ResMed (NYSE:RMD) has an average broker rating of 3.28, which is interpreted as a Hold, as rated by 9 equity analysts. Nonetheless, 1 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Nevertheless, the majority of 4 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold. 3 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.
ResMed (NYSE:RMD) : Currently there are 7 street experts covering ResMed (NYSE:RMD) stock. The most bullish and bearish price target for the stock is $64 and $44 respectively for the short term. The average price target of all the analysts comes to $56.2. The estimated standard deviation from the target is $6.24.
Company shares have received an average consensus rating of Hold for the current week
ResMed (NYSE:RMD): stock turned positive on Tuesday. Though the stock opened at $60.12, the bulls momentum made the stock top out at $60.34 level for the day. The stock recorded a low of $59.31 and closed the trading day at $60.34, in the green by 1.89%. The total traded volume for the day was 818,828. The stock had closed at $59.22 in the previous days trading.
In an insider trading activity, The Securities and Exchange Commission has divulged that Farrell Michael J., officer (Chief Executive Officer) of Resmed Inc, had unloaded 5,975 shares at an average price of $59.63 in a transaction dated on June 15, 2016. The total value of the transaction was worth $356,289.
ResMed Inc. is engaged in the development, manufacturing, distribution and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing (SDB). The Company develops various products for SDB and other respiratory disorders, including airflow generators, diagnostic products, mask systems, headgear and other accessories. It produces continuous positive airway pressure, variable positive airway pressure and AutoSet systems for the titration and treatment of SDB. Its products also include S9 Escape, AirSense 10 Elite, AirSense 10 CPAP, S9 VPAP S, S9 VPAP ST, S9 VPAP Adapt, S9 VPAP ST-A, S9 VPAP COPD and AirCurve 10 V Auto, among others. It markets sleep recorders for the diagnosis and titration of SDB in sleep clinics and hospitals. Its products include Quattro FX, Swift FX for Her, Mirage FX for Her, Pixi Pediatric Mask, Quattro FX for Her, Swift FX Bella, Swift FX Nano, AirFit N10 and Apnealink Air.